Drugs / QAX028
last change Aug 2010 re-read 2 minutes ago

QAX028

Developed for
chronic obstructive pulmonary disease
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01068613 Jan → Aug 2010 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00568503 Comparator Oct 2007 → Feb 2008 chronic obstructive pulmonary disease Novartis Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as QAX028 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01068613
1

NCT00568503

Route Inhaled “QAX028 60 mcg via inhalation device” NCT01068613